Emerging Markets Forum: Pharma and OTC go-to-market strategies, partnerships and market access

13 - 14 March 2017

Dr. med. Dr. oec. Richard Ammer, born in Munich, graduated in medicine (Technical University Munich, Harvard Medical School Boston). His basic and clinical research on atrial fibrillation for which he obtained his PhD was awarded by the European Society in Cardiology with the Young Investigator Award in Basic Science in 2001 (Stockholm).

Specializing in cardiac and renal care Dr. Ammer pursued his clinical education in internal medicine at Massachusetts General Hospital in Boston (1996-2000), the German Heart Center (2000-2001) and the University Hospital in Muenster (since 2001), where today he is responsible for patients undergoing dialysis and renal transplant and where he runs the anemia unit. He also established the nation-wide network of excellence and competence on cardiac arrhythmias (BMBF sponsored) which he ran as general manager from 2002 to 2004 www.kompetenznetze-medizin.de.

His studies in business administration and economics he pursued at University St. Gallen (1992-1996), and Harvard Extension School (1996 -1999) completing his PhD in 2005. Since 2001 Dr. Ammer is assistant professor at University St. Gallen (CH).

In the family-owned pharmaceutical company MEDICE Dr. Ammer is active as managing owner, as general manager since 2003 responsible for search & development, medical & regulatory affairs, manufacturing, market access and international marketing & distribution.  

In parallel, since 2006 Dr. Ammer is board member and VP of the German Pharmaceutical Association with a focus on R&D www.BPI.de

SAVERIO has more than 20 years of career experience in Pharmaceutical Industry managing different technical and business areas in multinationals companies such as Merck and BMS. In the last 9 years, Saverio has been working for ACHE PHARMACEUTICAL LABS S/A, the Top Brazilian Pharma Company as Head of Innovation, Business Development and responsible for Strategic Alliances and all Internationalization initiatives. His focus lies on R&D programs, Pharmaceutical Technologies, Marketing, Business Development and M&A. Saverio is Brazilian and holds a technical background with a Pharma Degree besides of a diploma in Marketing and a Master’s in Business Administration from University of Sao Paulo – USP in Brazil.

Dr. Emara is a Healthcare operator & investor, enjoying a very strong international operational background & a solid track record of Private Equity Deals where he assumes the responsibility of Identifying and implementing best practices, business process assessments, mapping and process re-engineering.


He has also founded and been managing partner of several entrepreneurial ventures including Muse, a healthcare M&A and advisory firm, and Tech. Developers, an intellectual property commercialization venture.


-In addition, he has founded and has been Managing Partner of several entrepreneurial ventures including Muse, a healthcare M&A and managing-advisory firm, and Tech. Developers, a pioneer intellectual- properties-commercialization corporation. Earlier, Dr. Emara held various senior management positions in affiliations with distinguished multinational companies like Sanofi, Bayer, Abbott, & Spimaco.

-Furthermore, he has held & still holds several positions of significant responsibilities:
•CEO of Jeddah BioCity, a pioneer life science venture-capital firm,
•Board Member, Exec & Finance Committ. of Arabio, first JV Biological plant in MENA
•Managing Director of ESD, a hazardous-medical-waste-management corporation
•Managing Director of BioScan, a unique cyclotron cancer-diagnostic center
•Board Director at SABA Medical, a 30 yrs old Ambulatory Healthcare group
•Managing Director & CEO of Metrek a chain of retail pharmacies and polyclinics.
•Chairman & CEO of Avrupagoz, a leading Turkish chain of ophthalmology centers.
•Managing Director & CEO of Zahrawi, Dubai-based distributor of Medical Devices.
•Chairman of Orzax, a Turkish production & marketing co. nutritional supplements.

As a "thought leader, Dr. Emara is a regular panelist and speaker on healthcare private equity & operational excellence at industry conferences.


Dr. Emara, received his Bachelor’s degree in Medicine & Surgery from Cairo University, Egypt in 1992 and earned his MBA from City University, Seattle, USA in 2001.

He further received executive certifications from Harvard, Stanford, Wharton, Insead, IMD, Chicago Booth and MIT.

Barbara is a Visiting Professor at Rotterdam School of Management and a former Professor of Practice in Leadership at Hult Ashridge Business School. She designs and delivers tailored executive education solutions in the areas of leadership and change. 

She has developed and taught on numerous in-company programmes for organisations including Unilever, GSK, Astra Zeneca, DSM, Thyssen Krupp and the BBC.

Barbara’s doctoral and subsequent research focuses on the importance of connecting management education to the workplace, a philosophy that informs her approach when working with organisations.

Prior to her career in management education, Barbara worked for 13 years in International Sales and Marketing in the retail and healthcare industries holding senior positions within Alliance Boots, and BASF Pharma

She has a BA Degree in German and Russian, an Executive MBA, a MSc in Training and Performance Management, a Masters in Organisational Change and a Doctorate in Education from the University of Oxford.  She has British Psychological Society Level A and B qualifications in psychometric testing.

Claudia Palme is a partner and managing director with boutique consulting firm 55east in Dubai, UAE.  She works as a senior advisor with the global and local Life Sciences and Health Care industry, focusing on new business models in Health Care, expansion in emerging markets, growth and restructuring strategies and investments in the Middle East and Africa. Claudia spent over 15 years in senior management roles in the pharmaceutical industry at Amgen and Novartis and in strategy consulting at the Boston Consulting Group and booz & company across geographies including Europe, the Middle East, Africa and Latin America. Most recently, she was head of Strategic Planning and Operations for the Middle East and Africa region at Amgen, where she led Amgen’s regional expansion and business development, including market entries into Iran and Africa and the integration of Mustafa Nevzat’s generics business.

Claudia holds a Master’s Degree in Public Administration from Harvard and a Master’s in Economics and Business Administration from LMU Munich. She has co-published a book on economic and social policy reforms in Germany and papers on German health care reform.

Mr. Reiner Christensen looks back on more than 20 years of substantial experience in OTC, Rx, food supplements and Medical Device products in General Management. He has previously worked for Ferrosan A/B (Copenhagen), Omega Pharma Group (Brussels) and Merck KGaA (Asia, Latin America, Europe & CEE/CIS), Hoechst AG (Frankfurt) and Richard Bitter AG (Vienna).

He has lived and worked in Asia, Latin America and different European countries.

His focus is on Strategy, Marketing, Business Development and M&A. Reiner is German and holds a Diploma in Industrial Engineering & Management (Dipl. Wirtschaftsingenieur) and an Executive MBA from Ashridge.

Cengiz Zaim is International Markets Sales and Marketing Director and the member of Management Leadership Team and New Product Committee at Abdi Ibrahim Pharmaceuticals, leading pharmaceutical company of Turkey, with exports more than 50 countries.

He has almost 15 years of experience in sales & marketing; people, organisation and alliance management, as well as business development & licensing at local and global level.

Before joining Abdi Ibrahim; Cengiz worked at different positions of Eczacibasi which is one of the largest holdings in Turkey and Zentiva Prague which is part of Sanofi Group and acquired Eczacibasi Pharmaceuticals.

He has broad market experience and intelligence in CIS, EMEA, and North America.


Dr. Haleh Hamedifar is founder of CinnaGen Group as well as CinnaGen’s 7 daughter companies. She was formerly advisor to the WHO regarding GMP & Quality Assurance of Vaccine and Biopharmaceuticals.

She joined CinnaGen Co. as QA consultant in 1998, and became CEO from 2001. Based on her background in pharmacy she drove a change in company strategy from from diagnostics to biopharmaceuticals.

She has managed several biosimilar projects which resulted in products that are now in national as well as regional markets. CinnaGen Group is currently the largest biopharmaceutical manufacturer in region for both its production capacity as well as the number of products in the market.


Dr. Hamefidar graduated at the top of her class at the Tehran University of Medical Sciences (TUMS) in 1995. She holds an MBA from Linkoping University, Sweden.

Valdemaras holds a medical degree from Vilnius University, Lithuania, and has Master Degree in Management from BI Norway. Valdemaras has more than 20 years of experience in the international pharmaceutical industry, working in business development and leadership roles for Menarini, GlaxoSmithKline and now GryNumber Health in Central & Eastern Europe.

Evaldas is a Medical Doctor who also has Master of Management Degree from BI Norway and holds Diploma of the Health Economics of Pharmaceuticals from Stockholm School of Economics. He has 20 years experience in neurology, fertility, rheumatology and oncology therapy areas working in market access and global commercial and medical roles in multinational pharmaceutical companies as well as general management roles throughout Central & Eastern Europe, Balkans.

Currently CEO of generic company present in SE Europe (Balkan area). Company has 3 manufacturing sites and 130 employees, producing quality generic and innovative CHC products.

Started carrier 19 years ago in PLIVA as medical representative, working through carrier mostly in marketing and sales functions (PLIVA, SANDOZ). In 2011 opened Alvogen representative office in Croatia launching first two biosimilars on Croatian market. From 2013 as executive director of startup company (PharmaS has launched in 2009).


Josef Kriegl joined the Management Board of M+W Central Europe GmbH as Managing Director in January 2016. He has been with M+W Group for 13 years and has more than 20 years of career experience in international facilities construction. Before Josef Kriegl joined M+W Group, he was with NNE Pharmaplan and Glatt Ingenieurtechnik where he was responsible for the project planning of pharmaceutical production facilities. When Josef Kriegl joined M+W Group, he took responsibility for the business in Austria. This included responsibility for all the business operations in South-eastern Europe. He has headed the management of the Eastern Europe region at M+W Group since 2013.

Torsten Roos is Managing Director at INSIGHT Health, the German based information and data service provider. He is member of the executive board and responsible for the expansion of international data panels, strategic alliances with data suppliers/partners and the development of new data strategies.

Before taking over this responsibility, he joined the former NDC Health in 2000 and implemented the company`s product portfolio for wholesalers and pharmacies. Till 2008 he served INSIGHT Health as director data source in Germany. During the international expansion of INSIGHT Health in the last years, Torsten established the company as strategic partner for wholesaler, retailers and pharmaceutical traders in Europe and managed the expansion in new data panels in several European countries.

Due to his functions and career, Torsten is an expert in Health Care Data and digital data contents. Torsten studied social science at Justus-Liebig-University, Gießen and University RheinMain, Wiesbaden and holds an MBA of the FOM University, Essen.  


Dr. Serdar Alpan is the Head of Biotechnology Group at TURGUT İlaçları A.Ş. since January 2014. TURGUT İlaçları A.Ş. is the leading biotech company in Turkey focused on establishment of a world class biotechnology infrastructure in Turkey and development of high quality biosimilar monoclonal antibodies. Dr. Alpan's industrial career began in 1998 in ECZACIBAŞI, where he served for eight years as a Technical Manager, focused on the strategic drug development for Turkish and European markets in collaboration with global pharmaceutical companies. This was followed by a variety of managerial positions with increasing responsibility in Technical, Clinical and Regulatory aspects of Strategic Drug Development. In 2008, he established TNC Pharmaceuticals, a technology company focusing on technical, clinical and regulatory drug development services for local and international pharmaceutical and biotech companies. After receiving his MD degree from Ankara University Medical School and PhD degree of Pharmacology from Anadolu University Faculty of Medicine, he specialised in Molecular Pharmacology at Harvard Medical School. He worked as post-doctoral research fellow in Prof. Arthur Pardee’s laboratory at Dana Farber Cancer Institute and Harvard Medical School and carried out some studies in fields of molecular pharmacology and biotechnology. He worked on the expression of the genes controlling cell proliferation cycle with using the “differential display” method developed by Prof. Pardee. On mammalian cell cultures, he investigated the genes controlling cell proliferation cycle and cell metabolism on molecular level. He became Associate Professor in 1997 and initiated Pharmacology education program at Yeditepe University Medical School in 1998 as the founding faculty. He became full Professor in 2008 and taught molecular medicine and molecular pharmacology lessons in doctoral and master programs of the Graduate School of Health Sciences in addition to School of Medicine. Dr. Alpan is married and has a daughter.

Anca Dalea,
Managing Director and co-founder of Chimimportexport Plurimex - a major pharmaceutical sales and distribution company in Romania. Anca holds a medical degree and specializes in Endocrinology and Pharmacy. She has more than 25 years of experience in the pharmaceutical sector, holding various positions in Marketing, Medical Advisory and Regulatory Affairs. In addition, Anca has personal experience in launching numerous products in Romania for many different therapeutic areas like: endocrinology, cardiology and internal medicine, neurology, pediatrics, gynecology, oncology, diabetes, orthopedics and others.

Professional Qualifications:

currently                Managing Director, INSIGHT Health GmbH & Co. KG, Marketing and Sales                              (since 2003)


July  2000               Director Marketing and Sales, INSIGHT Health GmbH & Co.KG


1998                      Marketing Degree St. Gallen, Switzerland


1986 - 2000            Director Marketing IMS Health & internationales Projectmanagement


1980 – 1986            Academic studies at Johann- Wolfgang-Goethe-University Frankfurt with


                            Degree in Anglistic (main focus: academic study of English philology)



Co-Founder of association „Healthcare Frauen e. V.“ supporting young women for future leadership


                            Co-author of the publication: 21 Erfolgsfrauen, 21 Karriere-Formeln

                            Profilers’s Publishing, Experts know-how for your success.

Konstantin von Alvensleben was appointed Chairman of the RIEMSER management board
with effect from the 1st of June 2015.
As the Managing Director of Schwarz Pharma France, England and Germany, Mr. von
Alvensleben has successfully shaped the development of Schwarz Pharma within these
markets, especially in the areas of Business Development and In-licensing as well as
Marketing and Sales. Following the takeover of Schwarz Pharma by UCB, he has as
Managing Director of UCB in Germany and Managing Director of Takeda since 2009
gained extensive experience of both the national and international pharmaceutical

• Managing Director with over 20 years experience in national and international general
management, marketing, sales and business development
• Strong management expertise in key European markets (Germany, UK, France,
Austria Switzerland), goal oriented with a consistent track record to outperform the
• Member of the board of directors of Takeda/Nycomed Germany
(research/production/commercial), General Manager and commercial head for the
combined Takeda cluster business, board member of the Takeda CH organisation
• Member of the VFA, LAWG, FSA board in Germany, ABPI and EMG board in the UK

Dr. Kockaya is a medical doctor and health economist. He has triple experience of public, private and academic practice in the Market Access field, particularly applied to large-sized pharmaceuticals and biotechs. He holds a master in Pharmacoeconomics and Pharmacoepidemiology, and a doctorate in Clinical Pharmacology and Medical Pharmacology. He completed a European Market Access Diploma Program in France and studied as a fellow at Temple University’s Center for Pharmaceutical Health Services Research in US. He has had several articles published in journals or posters presented in congresses. He is the lead editor of “Pharmaceutical Market Access in Emerging Markets”. He worked for the Ministry of Health of Turkey as health economist and a member of reimbursement sub-committee, and for medical device and pharmaceutical companies as Market Access lead. He is now International Market Access Director, also in charge of Pricing and Reimbursement in CarthaGenetics.

Born in the Czech Republic he has a MSc degree in Chemistry and a PhD degree in Biochemistry from the Charles University of Prague. Until 1993 he was Assistant Professor at the Department of Biochemistry, Faculty of Science, Charles University.

In the past 24 years he worked in the pharmaceutical industry and gained a wide range of experience and responsibilities as Managing Director of Janssen operation in the Czech Republic, and later, from 2004 as New Business Development Director of Emerging Markets (Russia, Turkey, Central Europe, M. East, W. Asia and Africa), and later as BD Director in Europe Mid-Sized Markets (Nordics and Baltics, Benelux, Alpine countries, Greece, Israel and C. Europe). As the EMEA region representative he contributed to or led numerous global, regional and local L&A projects signed by Janssen over last 12 years. At the end of January 2017 he has retired from Janssen EMEA, Johnson & Johnson.

He is a co-founder of the Pharma Licensing Group in Central and Eastern Europe and Vice-President of European Pharma Licensing Council. In 2013 he was elected as the first president of PLG CEE, and re-elected in 2016.

Michal Raciborski is responsible for managing Alira Health operations in Germany. Having started in 2009, Michal has developed a strong expertise in M&A and strategic consulting during his time at the Company. He is also co-founder of Central and Eastern European branch of Pharmaceutical Licensing Group. Michal holds a German and French degree as Dipl.-Kaufmann and diplômé des Grandes Ecoles from the European School of Management (ESCP Europe) in Berlin, Paris and London. Additionally, he has received a MSc degree from the CASS Business School in London, UK and a Magister degree from the University of Economics in Poznan, Poland. Furthermore, Michal has a strong background in M&A and ECM sectors acquired during his experience at Citi and Credit Suisse.